Deals
Sell, Spin or Keep? Pfizer in a Quandary on Advil-Chapstick Unit
- Pharmaceutical giant is weighing spinoff or keeping business
- Seismic retail changes have squeezed consumer-health profits
Pfizer in a Quandary Over Consumer-Health Business
This article is for subscribers only.
Pfizer Inc.’s attempt to unload its consumer-health business fizzled, but hanging on to the division a while longer may not be a headache for the world’s largest drugmaker.
British pharmaceutical giant GlaxoSmithKline Plc, the final prospective buyer, withdrew from the bidding Friday, ending for now a sale process that began in October. Reckitt Benckiser Group Plc, another potential buyer, pulled out earlier this week.